# Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

> **NCT07001592** · PHASE1 · RECRUITING · sponsor: **Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)** · enrollment: 18 (estimated)

## Conditions studied

- Gastric Neoplasms
- Esophageal Cancer
- Liver Cancer
- Liver Metastasis
- MSS-CRC
- MSS
- Gastric Adenocarcinoma
- Peritoneal Cancer
- Peritoneal Carcinoma
- Peritoneal Metastases
- MSI-H
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** vvDD-hIL-2-RG-1

## Key facts

- **NCT ID:** NCT07001592
- **Lead sponsor:** Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2028-04
- **Final completion:** 2028-05
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07001592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07001592, "Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07001592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*